Navigation Links
Anti-cancer drug discovery partnership formed between UMMC and Ole Miss
Date:5/17/2011

JACKSON, Miss. A new partnership to search for cancer-fighting drugs combines compound-identification and screening expertise at the University of Mississippi's National Center for Natural Products Research with the drug development and clinical-trials capabilities at the University of Mississippi Medical Center Cancer Institute.

An agreement announced today between the Oxford-based NCNPR and the Cancer Institute in Jackson creates the Drug Discovery Core, which will be directed by Dr. David Pasco, assistant director of the Natural Products Center and research professor in pharmacognosy.

The drug discovery process begins at the NCNPR, where researchers collect plants and other natural products, create extracts and screens them for activity against given targets. Under the new agreement the most promising anti-cancer compounds will be further isolated and sent to Jackson for development and testing.

"Cancer institutes usually have some type of drug discovery program," Pasco said. "Since Dr. Miele's arrival, Dr. Larry Walker (director of the NCNPR) and I have been talking with him about this venture."

Dr. Lucio Miele took the Cancer Institute directorship in summer 2009. He's worked to expand the institute's research mission by hiring scientists, purchasing high-tech equipment and forging partnerships with other institutions. Founding the Drug Discovery Core is a milestone in that effort.

"Development of new anti-cancer agents is one of the most important aspects if not the most important aspect of cancer research," Miele said. "The Natural Products Center has tremendous experience and this agreement increases the synergy between our two campuses.

"Natural products are a rich source of drug discovery and have yielded some of the most potent drugs we still use -- the best example being Taxol," Miele said, referencing a drug that UM researchers had a hand in developing as the NCNPR was first forming.


'/>"/>
Contact: Jack Mazurak
jmazurak@umc.edu
601-984-1970
University of Mississippi Medical Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Study suggests enzyme crucial to DNA replication may provide potent anti-cancer drug target
2. Scripps Research and MIT scientists discover class of potent anti-cancer compounds
3. Getting more anti-cancer medicine into the blood
4. Soft drink could enhance effects of an anti-cancer drug
5. Parkinsons disease: Excess of special protein identified as key to symptoms and possible new target for treatment with widely used anti-cancer drug imatinib
6. Researchers advance biosynthesis of potent anti-cancer drug Taxol
7. Researchers engineer microbes for low-cost production of anti-cancer drug, Taxol
8. Moffitt Cancer Center and GLG Pharma LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
9. Moffitt Cancer Center and GLG Pharma, LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
10. Program focuses on anti-cancer stem cell therapies
11. ASCO data highlight novel anti-cancer approach that exposes tumors to immune attack
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2013)... News) -- Animals make great companions for senior citizens, but ... car are far more likely to crash than those who ... new study included 2,000 licensed drivers aged 70 and older. ... often they drove with their pet in the car. ... risk was twice as high as among those who never ...
(Date:5/25/2013)... 2013 Studies from Johns Hopkins University ... excessive weight and their inability to get adequate sleep. ... weight can naturally relieve many symptoms. , Johns ... sleep quality was significantly associated with overall weight loss, ... dated November 6th, 2012, researchers monitored 77 participants ...
(Date:5/25/2013)... On May 20, 2013 the Sydney ... to discuss or plan for their eventual demise, but it ... released a Must-Do List to help people properly arrange for ... a personal fact sheet.” , While not a formal document, ... personal data. It may include a summary of assets, ...
(Date:5/25/2013)... New York,NY (PRWEB) May 25, 2013 ... SizeItUp officially declared the integration of the 2012 ... Lamborghini Aventador is the latest entrant in the list ... Designed intelligently, the vehicle is all set to thrill ... with vicious acceleration power and spectacular looks, the 2012 ...
(Date:5/25/2013)... Many orthodontists have thought about moving their ... cloud is. Most people would naturally assume that ... their cloud service and support would own and maintain ... selling, they'd be wrong. Cloud providers lease space ... facility that houses servers and related equipment to run ...
Breaking Medicine News(10 mins):Health News:Seniors More Likely to Crash When Driving With Pet: Study 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers Newly Improved hCG Diet Plans Capable of Delivering Better Sleep 2Health News:FuneralFinancials.com Releases Last Wishes Must-Do List 2Health News:Rim Fitments Provider SizeItUp Launches The Database Integration For The 2012 Lamborghini Aventador 2Health News:Cirrus Ortho Launches Cloud Computing for Orthodontic Industry That is Unlike Any Other 2
... MADISON, N.J., Sept. 4 Quest Diagnostics Incorporated (NYSE: ... services, today announced that it was again selected to be part of ... and DJSI North America). The company is in its sixth year on ... American Index (since 2005). , , According to Sustainable ...
... strategies , FRIDAY, Sept. 4 (HealthDay News) -- ... United Kingdom and Australia rethink their efforts to combat ... healthy diets and exercise -- aren,t working. , In ... , Australian researchers followed more than 250 overweight and ...
... , WASHINGTON, Sept. 4 Nurses appear to be taking ... according to a survey released today by the Center for American Nurses ... The Nurse Investor Education Survey reveals that nurses may be ... needs. In fact, most nurses say they do not know what those ...
... , , NEW HAVEN, Conn., Sept. 4 ... discovery, development and commercialization of novel antibiotics for the treatment ... Kassberg has joined the company as Chief Business Officer. In ... development activities. , , Mr. Kassberg, age ...
... NEW YORK, Sept. 4 Delcath Systems, Inc. (Nasdaq: ... proprietary treatment method for primary and metastatic cancers to the ... Surgery for the University of Pittsburgh School of Medicine will ... Third Annual Conference on Saturday, September 5, 2009 in Milan, ...
... ... end-to-end payment solutions for merchants across all distribution channels, and ClaimLogic, a leader ... a partnership today that enables ClaimLogic to provide PCI-compliant credit card processing services ... ...
Cached Medicine News:Health News:Quest Diagnostics Marks Sixth Year on Dow Jones Sustainability Index 2Health News:Nurses and Retirement Security: A Looming Crisis? 2Health News:Nurses and Retirement Security: A Looming Crisis? 3Health News:Rib-X Pharmaceuticals, Inc. Appoints Tom Kassberg Chief Business Officer 2Health News:Delcath Systems, Inc. to Present Poster at International Liver Cancer Association 2009 Annual Conference 2Health News:EPX and ClaimLogic Announce Credit Card Processing Partnership 2Health News:EPX and ClaimLogic Announce Credit Card Processing Partnership 3
(Date:5/24/2013)... NEW YORK , May 24, 2013 In ... Takeover Rules and Rule 14e-1 of the United States Exchange ... levels its original offer for Elan Corporation (NYSE: ELN). ... Acquisition Limited ("Royalty Pharma") made an offer for the entire ... Elan Corporation, plc ("Elan") (the "Original Offer").  ...
(Date:5/24/2013)... and BOSTON , May 24, 2013 ... and development company, is pleased to announce that it has engaged ... augment the Company,s business development capabilities in Japan ... than 15 years of experience in business development, licensing and alliance ... Inc., Roche Pharma ( Japan ), Nippon Roche and ...
(Date:5/23/2013)... PARÍS, 24 de mayo de 2013  Volcano ... desarrollador y fabricante de herramientas de precisión para ... tratamiento de la enfermedad vascular periférica y coronaria, ... ( Ad enosine V asodilator I ... durante la sesión de ensayo clínico hot line ...
Breaking Medicine Technology:Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9Heptares Augments Business Development Capabilities in Japan and Other Asian Territories 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
... and SAN DIEGO, Nov. 12 Tobira Therapeutics, ... and product discovery for the treatment of life-threatening ... and results from two double-blind, placebo-controlled studies of ... studies, a single-ascending dose (SAD) study and the ...
... , BOTHELL, Wash., Nov. 11 ... ), a global leader in automated external defibrillator ( ... appointed Peter Kingma as senior vice president, effective immediately. ... Marver, president and chief executive officer, and oversees the ...
Cached Medicine Technology:Tobira Therapeutics Announces Presentation of TBR-652 Data at European AIDS Conference 2Cardiac Science Appoints Peter Kingma Senior Vice President Sales and Marketing 2Cardiac Science Appoints Peter Kingma Senior Vice President Sales and Marketing 3Cardiac Science Appoints Peter Kingma Senior Vice President Sales and Marketing 4Cardiac Science Appoints Peter Kingma Senior Vice President Sales and Marketing 5
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: